Avenue therapeutics to present at american epilepsy society 2023 annual meeting

Miami, dec. 01, 2023 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that amy chappell, m.d., faan, will be presenting preclinical in vivo data evaluating baer-101 using the synapcell's genetic absence epilepsy rat from strasbourg (“gaers”) model of absence epilepsy at the american epilepsy society (aes) 2023 annual meeting in orlando, fl on december 2, 2023.
ATXI Ratings Summary
ATXI Quant Ranking